{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:28:37Z","timestamp":1780824517186,"version":"3.54.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ebola virus (EBOV) is highly pathogenic, with a predisposition to cause outbreaks in human populations accompanied by significant mortality. An ovine polyclonal antibody therapy has been developed against EBOV, named EBOTAb. When tested in the stringent guinea pig model of EBOV disease, EBOTAb has been shown to confer protection at levels of 83.3%, 50% and 33.3% when treatment was first started on days 3, 4 and 5 post-challenge, respectively. These timepoints of when EBOTAb treatment was initiated correspond to when levels of EBOV are detectable in the circulation and thus mimic when treatment would likely be initiated in human infection. The effects of EBOTAb were compared with those of a monoclonal antibody cocktail, ZMapp, when delivered on day 3 post-challenge. Results showed ZMapp to confer complete protection against lethal EBOV challenge in the guinea pig model at this timepoint. The data reported demonstrate that EBOTAb is an effective treatment against EBOV disease, even when delivered late after infection.<\/jats:p>","DOI":"10.1038\/srep30497","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T12:13:28Z","timestamp":1469708008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic"],"prefix":"10.1038","volume":"6","author":[{"given":"Stuart D.","family":"Dowall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bosworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Landon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Coxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Al Abdulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"BFsrep30497_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","volume":"371","author":"S Baize","year":"2014","unstructured":"Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. The New England journal of medicine 371, 1418\u20131425, doi: 10.1056\/NEJMoa1404505 (2014).","journal-title":"The New England journal of medicine"},{"key":"BFsrep30497_CR2","unstructured":"WHO. Ebola haemorrhagic fever in Zaire, 1976. Bulletin of the World Health Organization 56, 271\u2013293 (1978)."},{"key":"BFsrep30497_CR3","doi-asserted-by":"publisher","first-page":"g5539","DOI":"10.1136\/bmj.g5539","volume":"349","author":"A Gulland","year":"2014","unstructured":"Gulland, A. First Ebola treatment is approved by WHO. Bmj 349, g5539, doi: 10.1136\/bmj.g5539 (2014).","journal-title":"Bmj"},{"key":"BFsrep30497_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3201\/eid2103.141838","volume":"21","author":"TR Kreil","year":"2015","unstructured":"Kreil, T. R. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerging infectious diseases 21, 521\u2013523, doi: 10.3201\/eid2103.141838 (2015).","journal-title":"Emerging infectious diseases"},{"key":"BFsrep30497_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/v4091619","volume":"4","author":"BM Friedrich","year":"2012","unstructured":"Friedrich, B. M. et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 4, 1619\u20131650, doi: 10.3390\/v4091619 (2012).","journal-title":"Viruses"},{"key":"BFsrep30497_CR6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(03)15012-X","volume":"362","author":"TW Geisbert","year":"2003","unstructured":"Geisbert, T. W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa\/tissue factor: a study in rhesus monkeys. Lancet 362, 1953\u20131958, doi: 10.1016\/S0140-6736(03)15012-X (2003).","journal-title":"Lancet"},{"key":"BFsrep30497_CR7","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1086\/520598","volume":"196","author":"LE Hensley","year":"2007","unstructured":"Hensley, L. E. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. The Journal of infectious diseases 196 Suppl 2, S390\u2013S399, doi: 10.1086\/520598 (2007).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.2202","volume":"16","author":"TK Warren","year":"2010","unstructured":"Warren, T. K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature medicine 16, 991\u2013994, doi: 10.1038\/nm.2202 (2010).","journal-title":"Nature medicine"},{"key":"BFsrep30497_CR9","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1086\/504267","volume":"193","author":"TW Geisbert","year":"2006","unstructured":"Geisbert, T. W. et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. The Journal of infectious diseases 193, 1650\u20131657, doi: 10.1086\/504267 (2006).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR10","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","volume":"375","author":"TW Geisbert","year":"2010","unstructured":"Geisbert, T. W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896\u20131905, doi: 10.1016\/S0140-6736(10)60357-1 (2010).","journal-title":"Lancet"},{"key":"BFsrep30497_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/infdis\/jiq025","volume":"203","author":"IC Michelow","year":"2011","unstructured":"Michelow, I. C. et al. High-dose mannose-binding lectin therapy for Ebola virus infection. The Journal of infectious diseases 203, 175\u2013179, doi: 10.1093\/infdis\/jiq025 (2011).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR12","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1128\/AAC.01315-09","volume":"54","author":"TK Warren","year":"2010","unstructured":"Warren, T. K. et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrobial agents and chemotherapy 54, 2152\u20132159, doi: 10.1128\/AAC.01315-09 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep30497_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2009.06.001","volume":"83","author":"MJ Aman","year":"2009","unstructured":"Aman, M. J. et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral research 83, 245\u2013251, doi: 10.1016\/j.antiviral.2009.06.001 (2009).","journal-title":"Antiviral research"},{"key":"BFsrep30497_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.tim.2014.04.002","volume":"22","author":"G Wong","year":"2014","unstructured":"Wong, G., Qiu, X., Olinger, G. G. & Kobinger, G. P. Post-exposure therapy of filovirus infections. Trends in microbiology 22, 456\u2013463, doi: 10.1016\/j.tim.2014.04.002 (2014).","journal-title":"Trends in microbiology"},{"key":"BFsrep30497_CR15","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","volume":"3","author":"H Feldmann","year":"2007","unstructured":"Feldmann, H. et al. Effective post-exposure treatment of Ebola infection. PLoS pathogens 3, e2, doi: 10.1371\/journal.ppat.0030002 (2007).","journal-title":"PLoS pathogens"},{"key":"BFsrep30497_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353, doi: 10.1038\/nature13777 (2014).","journal-title":"Nature"},{"key":"BFsrep30497_CR17","doi-asserted-by":"publisher","first-page":"7754","DOI":"10.1128\/JVI.00173-13","volume":"87","author":"X Qiu","year":"2013","unstructured":"Qiu, X. et al. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs. Journal of virology 87, 7754\u20137757, doi: 10.1128\/JVI.00173-13 (2013).","journal-title":"Journal of virology"},{"key":"BFsrep30497_CR18","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson, E. et al. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. Journal of virology 89, 10982\u201310992, doi: 10.1128\/JVI.01490-15 (2015).","journal-title":"Journal of virology"},{"key":"BFsrep30497_CR19","doi-asserted-by":"crossref","unstructured":"Alfson, K. J., Worwa, G., Carrion, R., Jr. & Griffiths, A. Determination of the Spontaneous Mutation Frequency of Ebola virus and Exploitation of this Therapeutically. Journal of virology, doi: 10.1128\/JVI.02701-15 (2015).","DOI":"10.1128\/JVI.02701-15"},{"key":"BFsrep30497_CR20","doi-asserted-by":"crossref","unstructured":"Dowall, S. D. et al. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. The Journal of infectious diseases, doi: 10.1093\/infdis\/jiv565 (2015).","DOI":"10.1093\/infdis\/jiv565"},{"key":"BFsrep30497_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1678-9199-19-27","volume":"19","author":"AG Habib","year":"2013","unstructured":"Habib, A. G. Public health aspects of snakebite care in West Africa: perspectives from Nigeria. The journal of venomous animals and toxins including tropical diseases 19, 27, doi: 10.1186\/1678-9199-19-27 (2013).","journal-title":"The journal of venomous animals and toxins including tropical diseases"},{"key":"BFsrep30497_CR22","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.celrep.2015.08.038","volume":"12","author":"JR Kugelman","year":"2015","unstructured":"Kugelman, J. R. et al. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Cell reports 12, 2111\u20132120, doi: 10.1016\/j.celrep.2015.08.038 (2015).","journal-title":"Cell reports"},{"key":"BFsrep30497_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2764","volume":"10","author":"JM White","year":"2012","unstructured":"White, J. M. & Schornberg, K. L. A new player in the puzzle of filovirus entry. Nature reviews. Microbiology 10, 317\u2013322, doi: 10.1038\/nrmicro2764 (2012).","journal-title":"Nature reviews. Microbiology"},{"key":"BFsrep30497_CR24","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gonzalez, E. et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Critical reviews in biotechnology, 1\u201316, doi: 10.3109\/07388551.2015.1114465 (2015).","DOI":"10.3109\/07388551.2015.1114465"},{"key":"BFsrep30497_CR25","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1086\/514305","volume":"179","author":"BM Connolly","year":"1999","unstructured":"Connolly, B. M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of infectious diseases 179 Suppl 1, S203\u2013S217, doi: 10.1086\/514305 (1999).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR26","doi-asserted-by":"crossref","unstructured":"Vogt, F. et al. Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. Euro surveillance: bulletin Europeen sur les maladies transmissibles\u2009=\u2009European communicable disease bulletin 20, doi: 10.2807\/1560-7917.ES.2015.20.50.30097 (2015).","DOI":"10.2807\/1560-7917.ES.2015.20.50.30097"},{"key":"BFsrep30497_CR27","doi-asserted-by":"publisher","first-page":"e1575","DOI":"10.1371\/journal.pntd.0001575","volume":"6","author":"X Qiu","year":"2012","unstructured":"Qiu, X. et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS neglected tropical diseases 6, e1575, doi: 10.1371\/journal.pntd.0001575 (2012).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep30497_CR28","doi-asserted-by":"publisher","first-page":"18030","DOI":"10.1073\/pnas.1213709109","volume":"109","author":"GG Olinger Jr.","year":"2012","unstructured":"Olinger, G. G., Jr. et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America 109, 18030\u201318035, doi: 10.1073\/pnas.1213709109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep30497_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4161\/hv.27813","volume":"10","author":"X Qiu","year":"2014","unstructured":"Qiu, X. & Kobinger, G. P. Antibody therapy for Ebola: is the tide turning around? Human vaccines & immunotherapeutics 10, 964\u2013967 (2014).","journal-title":"Human vaccines & immunotherapeutics"},{"key":"BFsrep30497_CR30","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1038\/srep06881","volume":"4","author":"J Audet","year":"2014","unstructured":"Audet, J. et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Scientific reports 4, 6881, doi: 10.1038\/srep06881 (2014).","journal-title":"Scientific reports"},{"key":"BFsrep30497_CR31","doi-asserted-by":"publisher","first-page":"138ra181","DOI":"10.1126\/scitranslmed.3003876","volume":"4","author":"X Qiu","year":"2012","unstructured":"Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Science translational medicine 4, 138ra181, doi: 10.1126\/scitranslmed.3003876 (2012).","journal-title":"Science translational medicine"},{"key":"BFsrep30497_CR32","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","volume":"372","author":"JB Varkey","year":"2015","unstructured":"Varkey, J. B. et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. The New England journal of medicine 372, 2423\u20132427, doi: 10.1056\/NEJMoa1500306 (2015).","journal-title":"The New England journal of medicine"},{"key":"BFsrep30497_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ijid.2015.12.011","volume":"43","author":"CR MacIntyre","year":"2015","unstructured":"MacIntyre, C. R. & Chughtai, A. A. Recurrence and reinfection-a new paradigm for the management of Ebola virus disease. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 43, 58\u201361, doi: 10.1016\/j.ijid.2015.12.011 (2015).","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"BFsrep30497_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","volume":"1","author":"B Kelley","year":"2009","unstructured":"Kelley, B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 1, 443\u2013452 (2009).","journal-title":"mAbs"},{"key":"BFsrep30497_CR35","doi-asserted-by":"publisher","first-page":"g5488","DOI":"10.1136\/bmj.g5488","volume":"349","author":"MUS McCarthy","year":"2014","unstructured":"McCarthy, M. U. S. signs contract with ZMapp maker to accelerate development of the Ebola drug. Bmj 349, g5488, doi: 10.1136\/bmj.g5488 (2014).","journal-title":"Bmj"},{"key":"BFsrep30497_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.chroma.2015.02.013","volume":"1389","author":"A Fulton","year":"2015","unstructured":"Fulton, A., Lai, H., Chen, Q. & Zhang, C. Purification of monoclonal antibody against Ebola GP1 protein expressed in Nicotiana benthamiana. Journal of chromatography. A 1389, 128\u2013132, doi: 10.1016\/j.chroma.2015.02.013 (2015).","journal-title":"Journal of chromatography. A"},{"key":"BFsrep30497_CR37","doi-asserted-by":"publisher","first-page":"20690","DOI":"10.1073\/pnas.1108360108","volume":"108","author":"L Zeitlin","year":"2011","unstructured":"Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proceedings of the National Academy of Sciences of the United States of America 108, 20690\u201320694, doi: 10.1073\/pnas.1108360108 (2011).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep30497_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nri1154","volume":"3","author":"H Feldmann","year":"2003","unstructured":"Feldmann, H., Jones, S., Klenk, H. D. & Schnittler, H. J. Ebola virus: from discovery to vaccine. Nature reviews. Immunology 3, 677\u2013685, doi: 10.1038\/nri1154 (2003).","journal-title":"Nature reviews. Immunology"},{"key":"BFsrep30497_CR39","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/JVI.02836-14","volume":"89","author":"G Wong","year":"2015","unstructured":"Wong, G. et al. Ebola virus transmission in guinea pigs. Journal of virology 89, 1314\u20131323, doi: 10.1128\/JVI.02836-14 (2015).","journal-title":"Journal of virology"},{"key":"BFsrep30497_CR40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4269\/ajtmh.14-0719","volume":"92","author":"T O\u2019Dempsey","year":"2015","unstructured":"O\u2019Dempsey, T., Khan, S. H. & Bausch, D. G. Rethinking the discharge policy for Ebola convalescents in an accelerating epidemic. The American journal of tropical medicine and hygiene 92, 238\u2013239, doi: 10.4269\/ajtmh.14-0719 (2015).","journal-title":"The American journal of tropical medicine and hygiene"},{"key":"BFsrep30497_CR41","doi-asserted-by":"publisher","first-page":"007","DOI":"10.4172\/2157-2526","volume":"S1","author":"JS Richardson","year":"2011","unstructured":"Richardson, J. S. et al. Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents. Journal of bioterrorism & biodefense S1, 007, doi: 10.4172\/2157-2526 (2011).","journal-title":"Journal of bioterrorism & biodefense"},{"key":"BFsrep30497_CR42","doi-asserted-by":"publisher","first-page":"207ra143","DOI":"10.1126\/scitranslmed.3006605","volume":"5","author":"X Qiu","year":"2013","unstructured":"Qiu, X. et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Science translational medicine 5, 207ra143, doi: 10.1126\/scitranslmed.3006605 (2013).","journal-title":"Science translational medicine"},{"key":"BFsrep30497_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1053\/jhep.2001.21747","volume":"33","author":"KR Reddy","year":"2001","unstructured":"Reddy, K. R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33, 433\u2013438, doi: 10.1053\/jhep.2001.21747 (2001).","journal-title":"Hepatology"},{"key":"BFsrep30497_CR44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1128\/IAI.05684-11","volume":"80","author":"A Roberts","year":"2012","unstructured":"Roberts, A. et al. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infection and immunity 80, 875\u2013882, doi: 10.1128\/IAI.05684-11 (2012).","journal-title":"Infection and immunity"},{"key":"BFsrep30497_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/1060028014555711","volume":"49","author":"MR Lepak","year":"2015","unstructured":"Lepak, M. R., Bochenek, S. H. & Bush, S. P. Severe adverse drug reaction following Crotalidae Polyvalent Immune Fab (Ovine) administration for copperhead snakebite. The Annals of pharmacotherapy 49, 145\u2013149, doi: 10.1177\/1060028014555711 (2015).","journal-title":"The Annals of pharmacotherapy"},{"key":"BFsrep30497_CR46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/1060028015571964","volume":"49","author":"ME Mullins","year":"2015","unstructured":"Mullins, M. E., Liss, D. B. & Schwarz, E. S. Comment: severe anaphylactic reaction following crotalidae polyvalent immune fab (ovine) administration for copperhead snakebite. The Annals of pharmacotherapy 49, 496, doi: 10.1177\/1060028015571964 (2015).","journal-title":"The Annals of pharmacotherapy"},{"key":"BFsrep30497_CR47","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1038\/nm1142","volume":"10","author":"TW Geisbert","year":"2004","unstructured":"Geisbert, T. W. & Jahrling, P. B. Exotic emerging viral diseases: progress and challenges. Nature medicine 10, S110\u2013S121, doi: 10.1038\/nm1142 (2004).","journal-title":"Nature medicine"},{"key":"BFsrep30497_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-3542(02)00005-0","volume":"54","author":"M Bray","year":"2002","unstructured":"Bray, M. & Paragas, J. Experimental therapy of filovirus infections. Antiviral research 54, 1\u201317 (2002).","journal-title":"Antiviral research"},{"key":"BFsrep30497_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/path.1711250303","volume":"125","author":"A Baskerville","year":"1978","unstructured":"Baskerville, A., Bowen, E. T., Platt, G. S., McArdell, L. B. & Simpson, D. I. The pathology of experimental Ebola virus infection in monkeys. The Journal of pathology 125, 131\u2013138, doi: 10.1002\/path.1711250303 (1978).","journal-title":"The Journal of pathology"},{"key":"BFsrep30497_CR50","first-page":"227","volume":"76","author":"E Johnson","year":"1995","unstructured":"Johnson, E., Jaax, N., White, J. & Jahrling, P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. International journal of experimental pathology 76, 227\u2013236 (1995).","journal-title":"International journal of experimental pathology"},{"key":"BFsrep30497_CR51","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3201\/eid1406.071489","volume":"14","author":"MG Kortepeter","year":"2008","unstructured":"Kortepeter, M. G. et al. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerging infectious diseases 14, 881\u2013887, doi: 10.3201\/eid1406.071489 (2008).","journal-title":"Emerging infectious diseases"},{"key":"BFsrep30497_CR52","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1086\/514285","volume":"179","author":"P Formenty","year":"1999","unstructured":"Formenty, P. et al. Human infection due to Ebola virus, subtype Cote d\u2019Ivoire: clinical and biologic presentation. The Journal of infectious diseases 179 Suppl 1, S48\u2013S53, doi: 10.1086\/514285 (1999).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","volume":"2","author":"RT Emond","year":"1977","unstructured":"Emond, R. T., Evans, B., Bowen, E. T. & Lloyd, G. A case of Ebola virus infection. British medical journal 2, 541\u2013544 (1977).","journal-title":"British medical journal"},{"key":"BFsrep30497_CR54","doi-asserted-by":"publisher","first-page":"S785","DOI":"10.1093\/infdis\/jir298","volume":"204","author":"S Gunther","year":"2011","unstructured":"Gunther, S. et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. The Journal of infectious diseases 204 Suppl 3, S785\u2013S790, doi: 10.1093\/infdis\/jir298 (2011).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep30497_CR55","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1017\/ice.2015.205","volume":"36","author":"DJ Weber","year":"2015","unstructured":"Weber, D. J., Fischer, W. A., Wohl, D. A. & Rutala, W. A. Protecting healthcare personnel from acquiring Ebola virus disease. Infection control and hospital epidemiology 36, 1229\u20131232, doi: 10.1017\/ice.2015.205 (2015).","journal-title":"Infection control and hospital epidemiology"},{"key":"BFsrep30497_CR56","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.virusres.2015.09.002","volume":"210","author":"O Cenciarelli","year":"2015","unstructured":"Cenciarelli, O. et al. Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013-2015. Virus research 210, 318\u2013326, doi: 10.1016\/j.virusres.2015.09.002 (2015).","journal-title":"Virus research"},{"key":"BFsrep30497_CR57","doi-asserted-by":"crossref","unstructured":"Kuhn, J. H. et al. Reidentification of Ebola Virus E718 and ME as Ebola Virus\/H.sapiens-tc\/COD\/1976\/Yambuku-Ecran. Genome announcements 2, doi: 10.1128\/genomeA.01178-14 (2014).","DOI":"10.1128\/genomeA.01178-14"},{"key":"BFsrep30497_CR58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/PREACCEPT-1724277741482641","volume":"15","author":"SD Dowall","year":"2014","unstructured":"Dowall, S. D. et al. Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome biology 15, 540, doi: 10.1186\/PREACCEPT-1724277741482641 (2014).","journal-title":"Genome biology"},{"key":"BFsrep30497_CR59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.antiviral.2012.11.003","volume":"97","author":"S Dowall","year":"2013","unstructured":"Dowall, S. et al. Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral research 97, 108\u2013111, doi: 10.1016\/j.antiviral.2012.11.003 (2013).","journal-title":"Antiviral research"},{"key":"BFsrep30497_CR60","doi-asserted-by":"publisher","first-page":"954","DOI":"10.4269\/ajtmh.2010.09-0636","volume":"82","author":"AR Trombley","year":"2010","unstructured":"Trombley, A. R. et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. The American journal of tropical medicine and hygiene 82, 954\u2013960, doi: 10.4269\/ajtmh.2010.09-0636 (2010).","journal-title":"The American journal of tropical medicine and hygiene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep30497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30497","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:03:10Z","timestamp":1672894990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep30497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,26]]}},"alternative-id":["BFsrep30497"],"URL":"https:\/\/doi.org\/10.1038\/srep30497","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"assertion":[{"value":"16 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Work was funded by the Public Health England pipeline fund and from MicroPharm Ltd. J.L., I.C., R.C. and I.A. are employees of MicroPharm Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30497"}}